pre-IPO PHARMA

COMPANY OVERVIEW

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. HS has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.


LOCATION

  • Tokyo, , Japan

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Regenerative Medicine

  • WEBSITE

    https://www.heartseed.jp/en/index.html


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    angel-bridge astellas-venture-management gene-techno-science jmdc nissay-capital sbi-investment smbc-capital


    PRESS RELEASES


    Sep 11, 2023

    Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology


    Sep 5, 2023

    Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy


    May 25, 2023

    Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure


    Jun 11, 2021

    Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure


    Nov 30, 2020

    Heartseed Named "Healthcare Company of the Year 2020” by Healthcare Insights Magazine in the MedTech Category for Making a Crucial Impact in Healthcare


    For More Press Releases


    Google Analytics Alternative